CEO Executive AssistantProduct launch is the moment of maximum organizational complexity in the pharmaceutical lifecycle. Every function in the organization converges on a single event, and the quality of execution across all of them determines whether years of development investment translate into the commercial success and patient impact the organization has worked toward.
For pharmaceutical CEOs, launch preparation creates extreme demands on strategic leadership simultaneously across commercial, medical affairs, regulatory, manufacturing, market access, and investor relations functions. Without a rigorous delegation model, the CEO becomes the bottleneck that slows every function simultaneously.
This guide describes how experienced pharmaceutical CEOs delegate launch preparation effectively, maintaining strategic oversight while enabling the cross-functional execution that launch excellence requires.
The Launch Preparation Landscape
A full commercial launch involves dozens of parallel workstreams that must be coordinated across every organizational function. Understanding the scope of this coordination is the first step to designing an effective delegation model.
Regulatory approval management. The final stages of regulatory review, advisory committee preparation, FDA review timeline management, and label negotiations require intensive regulatory affairs attention in the months before expected approval.
Commercial organization readiness. Sales force hiring, training, and deployment; marketing materials regulatory review; sales force call planning; and commercial operations activation must all be complete at launch.
Market access preparation. Formulary negotiation strategy, payer engagement, patient assistance program activation, and specialty pharmacy contracting must be operational before or at launch.
Medical affairs launch readiness. MSL deployment, KOL scientific exchange programs, medical education program activation, and medical information service readiness must be coordinated with the commercial launch timeline.
Supply chain and manufacturing readiness. Commercial manufacturing scale-up, inventory build, distribution network activation, and supply continuity plans must ensure adequate product supply at launch.
Patient services activation. Reimbursement support services, copay assistance programs, clinical support nursing, and patient assistance programs must be operational and publicized before launch.
Investor and public communications. Investor expectations, public announcements, media strategy, and stakeholder communications must be managed carefully around the regulatory review and launch timeline.
The CEO’s Launch Preparation Role
The CEO’s role in launch preparation is strategic oversight and organizational accountability, not operational management of any individual workstream.
Setting the launch vision and standards. The CEO defines what launch excellence looks like for the organization: what market share goals are realistic, what patient access outcomes are expected, what relationships the launch should build or strengthen. This vision gives the entire organization a shared destination.
Managing the launch governance process. A launch steering committee or launch readiness team, attended by the CEO, should provide the organizational forum for cross-functional launch coordination. The CEO’s role in this forum is to make decisions that require CEO authority, resolve cross-functional conflicts, and ensure accountability across all workstreams.
Investor and public communications leadership. The CEO is the primary voice in investor communications around regulatory approval and launch. A communications team prepares materials; the CEO presents and engages with investors.
Major strategic launch decisions. Pricing decisions, major market access strategy decisions, commercial partnership decisions, and significant resource allocation choices related to the launch require CEO engagement.
Accountability for launch performance. The CEO holds the CCO accountable for commercial performance, the CMO accountable for medical affairs launch readiness, the CRO accountable for regulatory approval timing, and the COO accountable for manufacturing readiness. Accountability is the CEO’s most important organizational governance tool.
Delegating Functional Launch Workstreams
Below the CEO’s strategic oversight, functional leaders own the operational management of each launch workstream.
Chief Commercial Officer: Commercial Launch Operations. The CCO owns the full commercial launch plan: sales force readiness, marketing activation, market access execution, patient services launch, and commercial performance management after launch. The CEO reviews commercial launch milestones and holds the CCO accountable for commercial readiness and performance.
Chief Medical Officer: Medical Affairs Launch. The CMO owns medical affairs launch readiness: MSL deployment and training, KOL pre-launch scientific exchange, medical education program activation, and medical information service readiness. The CEO ensures that medical and commercial activities are appropriately coordinated.
Chief Regulatory Officer: Regulatory Approval Management. The CRO owns the final stages of regulatory review: managing the FDA review clock, preparing for and responding to FDA requests, managing label negotiations, and ensuring that all regulatory approvals needed for launch are in hand.
COO/VP Manufacturing: Supply Readiness. Manufacturing and supply chain leadership owns supply readiness: ensuring that commercial manufacturing is validated and scaled, inventory is built to plan, distribution is contracted and ready, and supply continuity plans are in place for launch scenarios.
CFO: Financial Launch Planning. The CFO owns the financial dimensions of launch preparation: launch budget management, commercial forecasting, investor communication support, and financial risk management for launch scenarios.
For detailed guidance on the pharma product launch delegation framework, see our resource on pharma product launch.
Launch Readiness Reviews and CEO Oversight
A structured launch readiness review process gives the CEO visibility across all workstreams without requiring operational engagement in each.
A monthly launch readiness meeting, attended by the CEO and all functional leaders, should review the status of each major launch workstream against a predetermined readiness checklist. A traffic light system, where each workstream is rated green, yellow, or red based on readiness status, gives the CEO a quick cross-functional view.
When workstreams show yellow or red status, the CEO engages with the relevant functional leader to understand the gap and the resources or decisions needed to close it. Green workstreams require no CEO attention; the functional leader is performing.
This risk-based engagement model keeps the CEO informed and accountable for organizational readiness without pulling them into operational management of any individual function.
Managing Cross-Functional Launch Coordination
Launch preparation is fundamentally a cross-functional challenge, and the interfaces between functions are where most launch execution problems occur. The CEO must design the cross-functional coordination mechanisms that prevent interface failures.
A launch project management office, led by a program director with cross-functional authority, should own the operational coordination of launch preparation: maintaining the master launch timeline, tracking cross-functional dependencies, facilitating cross-functional working groups, and escalating coordination issues to the launch steering committee when they cannot be resolved at the working level.
The CEO is the organizational authority that resolves cross-functional conflicts when they reach the escalation threshold. But the PMO’s job is to resolve most cross-functional issues before they reach the CEO.
Regulatory Approval Uncertainty and Launch Planning
Pharmaceutical launch planning must account for regulatory timing uncertainty: approvals can arrive earlier or later than expected, and the launch plan must be robust to this uncertainty.
A commercial launch contingency planning function, led by the CCO working with the regulatory team, should develop scenario plans for launch at different approval timepoints. The CEO should understand the financial and operational implications of different approval scenarios and ensure that contingency plans are in place.
Launch planning should not assume a specific approval date without accounting for regulatory timing variability. The CEO’s role is to ensure that the organization plans for multiple scenarios rather than betting on a single timeline assumption.
Market Access and Payer Launch Readiness
For specialty pharmaceutical products, market access readiness is often the most critical determinant of launch performance. Formulary coverage at launch determines how many patients can access the therapy and what their out-of-pocket costs will be.
The VP of market access or head of managed care should own payer launch readiness: completing payer contracting, ensuring that patient assistance programs are operational, launching specialty pharmacy support programs, and activating the medical affairs market access support activities.
The CEO engages with market access strategy at the level of major decisions: pricing strategy approval, major payer contracting decisions, and responses to significant market access challenges.
Managing Launch Communications
The period around regulatory approval and commercial launch involves intensive external communications demands: investor communications about approval, media coverage of the approval and launch, healthcare provider communications, patient community communications, and payer communications.
A communications director should own the operational management of all external communications: preparing materials, managing media inquiries, coordinating with the IR team on investor communications, and managing the public announcement process.
The CEO is the primary public spokesperson at approval: the statement on approval, the investor call, the media interview, and the patient community communication all require CEO voice. Staff prepare; the CEO presents.
Launch Performance Management After Launch
The transition from launch preparation to launch execution and performance management is one of the most important organizational transitions in the pharmaceutical lifecycle.
The CEO’s role shifts from ensuring organizational readiness to monitoring commercial performance and holding functional leaders accountable for execution against launch goals. A weekly commercial performance review, attended by the CEO and commercial leadership, should track early launch metrics: prescription trends, market share, formulary coverage, and patient access data.
According to McKinsey and Company, pharmaceutical CEOs who maintain strategic oversight of launch preparation through rigorous readiness reviews while delegating functional execution to accountable commercial, medical, and regulatory leaders consistently achieve stronger launch performance than those who either micromanage launch activities or disengage from launch oversight.
The CEO’s Launch Legacy
A successful product launch is one of the most significant organizational achievements a pharmaceutical CEO can lead. Done well, it translates years of development investment into access for patients who need the therapy, revenue that funds the next generation of programs, and organizational confidence that the company can execute at the highest level.
Building the delegation model that makes launch excellence possible, one that provides CEO-level strategic oversight and accountability without CEO operational management of individual workstreams, is one of the most important leadership investments a pharmaceutical CEO can make.
For guidance on managing the ongoing pipeline delegation alongside launch preparation, see our resource on pharma drug pipeline.
The patients who will benefit from your product are waiting. Build the launch organization that will reach them effectively, and lead it with the strategic clarity and organizational accountability that distinguishes excellent pharmaceutical leadership.
Related Reading
For further context, explore How Pharma CEOs Delegate Business Development and Licensing and How Pharma CEOs Delegate Clinical Trial Operations.